title: Effect of allograft inflammatory factor-1 gene polymorphisms on rheumatoid arthritis treatment with methotrexate.
abstract: OBJECTIVE
  Methotrexate (MTX) in low doses is used in the therapy of rheumatoid arthritis (RA). The aim of many studies is to identify factors predicting the outcome of treatment with methotrexate in rheumatoid arthritis. The action of MTX in RA is associated with the inhibition of inflammatory mediators synthesis. AIF-1 is a cytokine playing a role in chronic inflammatory processes. The levels of AIF-1 were significantly increased in synovial fluid from patients with RA. The aim of this study was to investigate the association between AIF1 gene polymorphisms (rs2269475:C>T, rs2736182:G>A, rs2259571:A>C) and response to treatment of RA patients with MTX.
  
  
  METHODS
  The study was carried out on 221 patients diagnosed with active rheumatoid arthritis, treated with MTX. Good responders were defined as patients who were receiving MTX and had a DAS28 of ≤2.4 at 6 months.
  
  
  RESULTS
  With regard to the AIF1 rs2259571 polymorphism the remission of RA symptoms was observed in 52.99% of AA genotype carriers, in 45.25% of subjects with AC genotype, and in 32.84% with CC. The differences were statistically significant. CC vs AA p=0.03, OR 0.41, 95%CI (0.18-0.92).
  
  
  CONCLUSIONS
  The results of this study suggest that the patients with the rs2259571 CC AIF1 genotype have a poorer response to therapy with MTX.
authors.affiliation: Department of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Medical University, Szczecin, Poland.
authors.forename: Andrzej
authors.initials: A
authors.lastname: Pawlik
authors.forename: Maria-Magdalena
authors.initials: MM
authors.lastname: Herczynska
authors.forename: Violetta
authors.initials: V
authors.lastname: Dziedziejko
authors.forename: Damian
authors.initials: D
authors.lastname: Malinowski
authors.forename: Mateusz
authors.initials: M
authors.lastname: Kurzawski
authors.forename: Marek
authors.initials: M
authors.lastname: Drozdzik
authors.forename: Barbara
authors.initials: B
authors.lastname: Gawronska-Szklarz
mesh_terms: D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000235:genetics*; D002135:Calcium-Binding Proteins; D004268:DNA-Binding Proteins / Q000235:genetics*; D005260:Female; D060005:Genotyping Techniques; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008840:Microfilament Proteins; D008875:Middle Aged; D009687:Nuclear Proteins / Q000235:genetics*; D011110:Polymorphism, Genetic; D016896:Treatment Outcome
chemical_list: C112986:AIF1 protein, human; D002135:Calcium-Binding Proteins; D004268:DNA-Binding Proteins; D008840:Microfilament Proteins; D009687:Nuclear Proteins; D008727:Methotrexate